Sage Therapeutics, Inc.(SAGE)

Description: Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat rare central nervous system disorders. The company's lead product candidate includes SAGE-547, an intravenous (IV) agent that is in Phase I/II clinical development as an adjunctive therapy for the treatment of super-refractory status epilepticus (SRSE). Its products in IND-enabling toxicology and safety pharmacology testing comprise SAGE-689, an adjunctive second-line therapy for the treatment of status epilepticus (SE); and SAGE-217, an IV monotherapy for the treatment of refractory status epilepticus, as well as an orally delivered maintenance therapeutic to prevent recurrent seizures in patients whose SE, RSE, or SRSE has resolved. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is based in Cambridge, Massachusetts.

---

Keywords: Biopharmaceutical Drugs Pharmacology Clinical Development Gabaa Receptor Positive Allosteric Modulators Central Nervous System Disorders Anticonvulsants Toxicology Nervous System Disorders Antidepressants Seizure Neurosteroids Adjunctive Therapy Status Epilepticus

---

Home Page: www.sagerx.com

SAGE Technical Analysis

215 First Street
Cambridge, MA 02142
United States
Phone: 617 299 8380

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)